CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
CTS Spotlight at 2018 AABB Annual Meeting Sunday, October 14, 2018 at 1:30 PM: Scientific Oral ...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...